George Bakris to Cardiovascular System
This is a "connection" page, showing publications George Bakris has written about Cardiovascular System.
Connection Strength
2.856
-
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686.
Score: 0.724
-
Improvement of Cardiovascular Functional Reserve After Kidney Transplant-Has the CAPER Been Solved? JAMA Cardiol. 2020 04 01; 5(4):430-431.
Score: 0.708
-
The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494.
Score: 0.489
-
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98.
Score: 0.200
-
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
Score: 0.199
-
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659.
Score: 0.190
-
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
Score: 0.160
-
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012 Feb; 163(2):156-63.
Score: 0.100
-
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
Score: 0.043
-
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
Score: 0.043